Microsatellite Instability

Microsatellite Instability (MSI) is a form of genome instability characterized by a tendency toward expansion or contraction of short, tandemly repeated DNA sequences called microsatellites, arising from a deficiency in the DNA mismatch repair system that would normally correct the replication slippage errors these repetitive sequences are especially prone to generating. Unlike chromosomal instability and structural genome instability, which operate at the scale of whole chromosomes or large DNA segments, MSI is a small-scale, sequence-level instability phenotype, but one with equally significant consequences for tumor development and equally important clinical implications.

Microsatellites and Their Vulnerability to Error

What Microsatellites Are

Microsatellites are short DNA sequence motifs, typically one to six base pairs in length, repeated in tandem numerous times at a given genomic locus. They occur abundantly throughout the human genome, both in noncoding regions and, less frequently but consequentially, within or near coding sequences of specific genes.

Why Repetitive Sequence Is Error-Prone

During DNA replication, the repetitive nature of microsatellite sequence makes it particularly susceptible to polymerase slippage — a phenomenon in which the newly synthesized strand transiently dissociates and reanneals to the template at a different repeat unit, causing the DNA polymerase to either skip or duplicate one or more repeat units. This produces insertion or deletion loops that, if left uncorrected, become permanent changes in repeat number in subsequent generations of the cell.

The Mismatch Repair System and Its Failure

Normal Correction of Slippage Errors

The DNA mismatch repair (MMR) system, centered on the MLH1, MSH2, MSH6, and PMS2 protein complex, normally recognizes and corrects the insertion/deletion loops generated by polymerase slippage before they become fixed, maintaining microsatellite repeat lengths stably across cell divisions in MMR-proficient cells.

Consequences of MMR Deficiency

When one or more core MMR genes are inactivated — through inherited germline mutation, somatic mutation, or epigenetic silencing (most commonly MLH1 promoter hypermethylation) — the cell loses its capacity to correct slippage errors, and microsatellite repeat lengths begin to drift, expanding or contracting at a rate dramatically elevated above the MMR-proficient baseline, producing the MSI phenotype detectable in tumor DNA.

Elevated Genome-Wide Mutation Burden

Because MMR also corrects base-substitution mismatches beyond microsatellite slippage specifically, MMR-deficient tumors typically display an elevated overall mutation burden across the genome, not solely at microsatellite loci — MSI status is therefore both a direct consequence of and a marker for this broader hypermutator phenotype.

Hereditary and Sporadic Origins

Lynch Syndrome

Inherited germline mutations in MLH1, MSH2, MSH6, or PMS2 cause Lynch syndrome, a hereditary cancer predisposition syndrome markedly increasing lifetime risk of colorectal, endometrial, and several other cancers, in which tumors that arise following somatic loss of the remaining functional MMR allele display MSI as a defining molecular feature.

Sporadic MSI Tumors

The majority of MSI-positive tumors are not hereditary but arise sporadically, most commonly through somatic MLH1 promoter hypermethylation silencing its expression — a distinct mechanistic route to the same MMR-deficient, MSI-positive end state, requiring molecular or clinical criteria beyond MSI status alone to distinguish from Lynch syndrome-associated cases.

Consequences for Tumor Development

Frameshift Mutations in Coding Microsatellites

When a microsatellite lies within the coding sequence of a gene, slippage-induced insertion or deletion of repeat units that is not a multiple of three shifts the reading frame downstream, typically producing a truncated, non-functional protein — genes containing coding microsatellites are therefore recurrently inactivated in MSI tumors through this mechanism, contributing specific driver alterations distinct from those typically seen in chromosomally unstable tumors.

A Distinct Route to the Same Hallmarks

MSI-driven tumors tend to accumulate driver mutations through this frameshift-based mechanism at coding microsatellites and through the elevated genome-wide point mutation rate, representing an alternative evolutionary route to acquiring the hallmark capabilities of cancer compared to the chromosome-level route characteristic of CIN-driven tumors — the two instability phenotypes are generally considered largely mutually exclusive within a given tumor, reflecting distinct underlying evolutionary strategies rather than co-occurring mechanisms.

Clinical Significance

Diagnostic and Prognostic Use

MSI status is routinely assessed in colorectal and endometrial cancers, both to screen for possible underlying Lynch syndrome and because MSI status carries independent prognostic significance, generally associated with a more favorable stage-adjusted prognosis in colorectal cancer relative to microsatellite-stable tumors.

Immunotherapy Response Biomarker

The high mutation burden characteristic of MSI-high tumors generates a correspondingly large number of neoantigens, making these tumors disproportionately responsive to immune checkpoint inhibitor therapy — MSI status has become one of the most clinically actionable biomarkers in oncology, guiding treatment selection across multiple cancer types on the basis of MMR deficiency status regardless of the tumor's tissue of origin.

Detection Methods

PCR-Based Fragment Length Analysis

MSI can be assessed by comparing the length of a panel of standard microsatellite loci in tumor DNA against matched normal tissue, with instability at a defined threshold number of loci classifying a tumor as MSI-high, MSI-low, or microsatellite stable.

Immunohistochemistry for MMR Protein Loss

Loss of MLH1, MSH2, MSH6, or PMS2 protein expression, detectable by immunohistochemistry, serves as a complementary and widely used surrogate for MMR deficiency and MSI status, often used in clinical practice alongside or instead of direct microsatellite length analysis.

Practical Significance

Microsatellite Instability represents a distinct, sequence-level category of genome instability rooted in DNA mismatch repair deficiency, generating characteristic frameshift-driven gene inactivation and an elevated genome-wide mutation burden as its route to promoting tumor development, in contrast to the chromosome-level mechanisms underlying chromosomal instability. Its clinical importance is now substantial and growing, serving simultaneously as a marker for hereditary cancer syndrome screening, an independent prognostic factor, and one of the most reliable biomarkers guiding immune checkpoint inhibitor therapy selection in modern oncology practice.